CoChat

Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells

Sasidharan Nair, Varun, Toor, Salman M., Ali, Bassam R., Elkord, Eyad · 2018 · Expert Opinion on Therapeutic Targets

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: Breast cancer is the most commonly diagnosed cancer, and it is a leading cause of cancer-related deaths in females worldwide. Triple-negative breast cancer (TNBC) constitutes 15% of breast cancer and shows distinct metastasis profiles with poor prognosis. Strong PD-L1 expression has been observed in some tumors, supporting their escape from immune surveillance. Targeting PD-L1 could be a promising therapeutic approach in breast cancer patients. We investigated potential molecular mechanisms for constitutive expression of PD-L1 by inhibiting upstream STAT1 and STAT3 signals. METHODS: PD-L1 expression in three breast cancer cell lines was measured using quantitative PCR and western blotting. Activation of STAT1 and STAT3 was blocked using pharmacological inhibitors and siRNA. The mechanism underlying the constitutive expression of PD-L1 was investigated using ChIP and co-immunoprecipitation assays. RESULTS: We found that individual inhibition of STAT1 and STAT3 activation partially downregulated PD-L1, while combined inhibition completely downregulated PD-L1 expression. Moreover, our results suggest that pSTAT1-pSTAT3 dimerize in cytosol and translocate to the nucleus, where they bind to PD-L1 promoter and induce PD-L1 expression. CONCLUSION: These findings provide a rationale for combined targeting of STAT1 and STAT3 for the development of immune-based cancer therapies for down regulation of PD-L1 expression.

Overview

Integrity signals

Registry

Crossref · 10.1080/14728222.2018.1471137

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 50 references

Research works printed but not linked: 1

  1. Chaudhary B, 2016, Vaccines (Basel), 4

Cited by

See all 164

Metadata

Authors
Sasidharan Nair, V., Toor, S. M., Ali, B. R., & Elkord, E.
Affiliations
  • Cancer Research Center, Qatar Biomedical Research Institute, College of Science and Engineering, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar
  • Hamad bin Khalifa University (QA)
  • Al Ain University (AE)
  • University of Manchester (GB)
Corresponding author
Elkord, Eyad
Venue
Expert Opinion on Therapeutic Targets
Published
2018-05-02
Volume
22
Issue
6
Pages
547-557
ISSN
  • 1472-8222 (ISSN-L)
  • 1744-7631
OpenAlex
W2799532768
Cited by
159
References
50
Citations by year
2026: 8 · 2025: 13 · 2024: 40 · 2023: 34 · 2022: 21 · 2021: 16 · 2020: 11 · 2019: 13 · 2018: 3
FWCI
4.16
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Therapeutic Targets (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
Funders
Qatar Biomedical Research Institute (VR04)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
PD-L1, STAT1, STAT3, triple-negative breast cancer, immune checkpoint blockade, combination therapy, cancer immunotherapy, STAT3 inhibitor
MeSH terms
Breast Neoplasms, Female, Humans, Blotting, Western, Down-Regulation, Gene Expression Regulation, Neoplastic, RNA, Small Interfering, Cell Line, Tumor, STAT1 Transcription Factor, STAT3 Transcription Factor, Molecular Targeted Therapy, Real-Time Polymerase Chain Reaction, B7-H1 Antigen, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells. https://app.cochat.ai/papers/10.1080/14728222.2018.1471137
The paper
Sasidharan Nair, V., Toor, S. M., Ali, B. R., & Elkord, E. (2018). Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells. Expert Opinion on Therapeutic Targets. https://doi.org/10.1080/14728222.2018.1471137

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.